Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment i...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2020-11-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | https://actamedicaportuguesa.com/revista/index.php/amp/article/view/11503 |
Summary: | Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
|
---|---|
ISSN: | 0870-399X 1646-0758 |